Trump talks drug progress amid COVID-19 pandemic, but FDA chief Hahn urges caution

President Donald Trump gives a speech on HRAs
President Donald Trump said chloroquine to treat COVID-19 infections would be available by prescription very soon. (White House)

In a much-anticipated press conference Thursday, President Donald Trump said the U.S. has stepped up near-term efforts to advance and make available therapeutics to help patients with COVID-19 illnesses. But despite the urgency and the progress, FDA commissioner Stephen Hahn said it's important to learn more about all potential treatments.

Amid the pandemic, one drug that’s gained attention in various countries is chloroquine, a decades-old malaria med that's available for cheap. President Trump said the U.S. is going to make the drug available by prescription “almost immediately.” 

Chloroquine is already approved to treat malaria, and Hahn said investigators are planning a “large, pragmatic clinical trial” to learn more. But, the commissioner cautioned, it’s always important to get the “right drug” to the “right patient” at the “right dosage” at the “right time.” The wrong dose could actually hurt a patient’s condition, he added. 

Free Webinar

Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!

While chloroquine isn't approved for patients with novel coronavirus infections, Trump may have been referencing an off-label use for the medicine. It wasn't immediately clear how the drug would become available imminently.

Aside from chloroquine, the president and FDA commissioner Hahn talked about efforts to test Gilead’s remdesivir, originally developed for Ebola. Trump said that drug is “very close to approved,” but Hahn declined to specify potential approval timelines. 

Coronavirus tracker: Merck CEO calls on Americans to limit contact; FDA halts domestic inspections 

Other efforts are underway for plasma-based therapies and repurposing existing medicines, Hahn said at the press conference. 

Meanwhile, investigators have launched a vaccine trial “in record time,” the president said. It'll be 12 months before the study completes and the FDA could potentially approve the shot, Hahn said. 

Until then, antivirals and other drugs are intended to be a “bridge” for treatment until the medical community has a deployable vaccine, Hahn added. 

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.